Ligand id: 7995

Name: racotumomab

No information available.
Summary of Clinical Use
Racotumomab is approved in Cuba and Argentina for the treatment of recurrent or advanced non-small cell lung cancer (NSCLC).
A Phase III clinical trial (NCT01460472) for advanced NSCLC is underway. A Phase I study (NCT01598454) in pediatric patients with tumours expressing N-glycolylated gangliosides is ongoing and includes indications such as neuroblastoma, Ewing's sarcoma, Wilm's tumor, retinoblastoma and glioma.
Mechanism Of Action and Pharmacodynamic Effects
Monoclonal antibodies that mimic gangliosides highly expressed on tumour cells are able to elicit circulating antibodies specific to the corresponding ganglioside when they are injected into syngeneic or xenogeneic animals [2,7,12]. Racotumomab is one such antibody, and induces the patient's immune system to generate a response against the cancer-specific ganglioside GM3 [1], with the purpose of blocking tumor growth, slowing disease progression and ultimately increasing patient survival.